ADC Therapeutics
Innovating Science. Inspiring Hope.
266 employees · est. 2011 · Lausanne, Switzerland
ADC Therapeutics is the older company (2011 vs 2014); ADC Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | ADC Therapeutics | Synaffix |
|---|---|---|
| Founded | ||
| Founded | 2011 older | 2014 |
| Headquarters | ||
| Headquarters | Lausanne, Switzerland | Oss, The Netherlands |
| Employees | ||
| Employees | 266 larger | 63 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health and Wellness | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | Unknown | Acquired |
| Total Funding | ||
| Total Funding | $1.27B | $100.00M |
| Funding Rounds | ||
| Funding Rounds | 13 | 3 |
| Services | ||
| Services | Development of Antibody Drug Conjugates, Expansion of Cancer Treatment Products, Clinical Trial Innovation, Medical Affairs and Research | ADC Platform Licensing, Bispecific Antibody Development, Targeted Therapy Development, Out-licensing Technology for Cancer Therapeutics |
| Target Customers | ||
| Target Customers | Patients with Hematologic Cancers, Patients with Solid Tumors, Individuals with Relapsed or Refractory Cancer, Healthcare Providers in Oncology | Pharmaceutical Companies, Biotechnology Firms, Oncology Researchers, Strategic Partners in Therapeutics |
| Taxonomy | ||
| Taxonomy | Antibody Drug Conjugates (ADCs), Oncology, Hematological Cancers, Solid Tumors, Clinical-Stage Drug Development, Commercialization, CD19-directed Therapies, ZYNLONTA®, Pyrrolobenzodiazepine (PBD) Technology, Relapsed Or Refractory Diffuse Large B-cell Lymphoma, PSMA-targeting ADC, Cancer Treatment, Pharmaceutical Manufacturing, Drug Discovery, Biotechnology Innovation | Antibody-Drug Conjugates, ADC Technology Platform, Licensed Partnerships, Biotech Innovation, Clinical-Stage Development, Enzymatic Glycan Modification, Metal-Free Click Chemistry, Site-Specific Conjugation, Cancer Therapeutics, Immune Cell Engagers, Targeted Gene Therapy, Bispecific Antibodies, Patent Portfolio, Phase 1 Clinical Trials, High Growth Market Segments |
| Website | ||
| Website | adctherapeutics.com | synaffix.com |
About ADC Therapeutics
ADC Therapeutics, based in Switzerland, is a commercial-stage global leader in antibody drug conjugates (ADCs), dedicated to transforming cancer treatment. Founded in 2011, the company's expertise spans clinical development to manufacturing. With a focus on pioneering the ADC sector, their approved...
About Synaffix
Synaffix, a Lonza Company, is a pioneering biotech firm founded in 2014 and headquartered in The Netherlands. It boasts a proprietary, clinical-stage technology platform focused on antibody-drug conjugates (ADCs), renowned for optimizing safety and efficacy. The platform's value is underscored by m...
We will tell you when either one moves
BounceWatch watches ADC Therapeutics and Synaffix for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at ADC Therapeutics and Synaffix — by email.
Frequently Asked Questions
Compare ADC Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at ADC Therapeutics on 10 Jun 2026, and Synaffix on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.